Phototherapy for psoriasis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Psoriasis is a chronic genetically determined disease of a multifactorial nature associated with immune-mediated inflammation and characterized by a recurrent course with frequent associative damage to other organs and systems.

According to global recommendations, nowadays, despite the era of biologic therapy, phototherapy (PUVA and UVB) continues to occupy its important niche in the treatment of moderate-to-severe psoriasis, due to the pathogenetically justified therapeutic effect, safety and low cost of procedures.

The review provides detailed data on the mechanism of action, the effectiveness of phototherapy; as well as potential biomarkers of psoriasis (calprotectin, lipocalin 2, resistin), which can enhance an accuracy assessment of the effectiveness of the treatment and, if necessary, its timely correction, which will allow faster achievement of the desired effect resulting in improvement of the quality of patients’ lives.

Full Text

Restricted Access

About the authors

Olga S. Yazkova

Central polyclinic

Email: olesha230808@mail.ru
ORCID iD: 0000-0002-9644-4778

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Ekaterina M. Anpilogova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: truelass@hotmail.com
ORCID iD: 0000-0001-9478-5838
SPIN-code: 8499-0506
Russian Federation, Moscow

References

  1. Olisova OY, Teplyuk NP, Pinegin VB. Modern methodes of psoriasis treatment. Russ J Med. 2015;(9):483–486. (In Russ).
  2. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997): 983–994. doi: 10.1016/S0140-6736(14)61909-7
  3. Ministry of Health of Russian Federation. The incidence of Russian population in 2020. Statistical data. Part 1. Moscow; 2021. Р. 111–112. (In Russ).
  4. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775–804. doi: 10.1016/j.jaad.2019.04.042
  5. Racz E, Prens E. Phototherapy of psoriasis, a chronic inflammatory skin disease. Adv Exp Med Biol. 2017;996:287–294. doi: 10.1007/978-3-319-56017-5_24
  6. Ceović R, Pasić A, Lipozencić J, et al. Antiproliferative, antiangiogenic and apoptotic effect of photochemotherapy (PUVA) in psoriasis patients. Coll Antropol. 2007;31(2):551–556.
  7. Johnson R, Staiano-Coico L, Austin L, et al. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes // Photochem Photobiol. 1996;63(5): 566–571. doi: 10.1111/j.1751-1097.1996.tb05657.x
  8. Ceović R, Pasić A, Lipozencić J, et al. Antiproliferative, antiangiogenic and apoptotic effect of photochemotherapy (PUVA) in psoriasis patients. Coll Antropol. 2007;31(2):551–556.
  9. Ravić-Nikolić A, Radosavljević G, Jovanović I, et al. Systemic photochemotherapy decreases the expression of IFN-γ, IL-12p40 and IL-23p19 in psoriatic plaques. Eur J Dermatol. 2011;21(1):53–57. doi: 10.1684/ejd.2010.1199
  10. Furuhashi T, Saito C, Torii K, et al. Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS One. 2013;8(1):e54895. doi: 10.1371/journal.pone.0054895
  11. Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282–1290. doi: 10.1111/j.1365-2133.2010.09992.x
  12. Hönigsmann H, Schwarz T. Ultraviolet therapy. In: Bolognia 12. JL, Jorizzo JL, Schaffer JV (editors). Dermatology. 3rd ed. Amsterdam, the Netherlands: Elsevier; 2012. Р. 2219–2235.
  13. Khan A, Bai H, Liu E, et al. Protective effect of neferine against UV-B-mediated oxidative damage in human epidermal keratinocytes. J Dermatolog Treat. 2018;29(7):733–741. doi: 10.1080/09546634.2018.1441490
  14. Landeck L, Jakasa I, Dapic I, et al. The effect of epidermal levels of urocanic acid on 25-hydroxyvitamin D synthesis and inflammatory mediators upon narrowband UVB irradiation. Photodermatol Photoimmunol Photomed. 2016;32(4):214–223. doi: 10.1111/phpp.12249
  15. Okhlopkov VA, Poleshchuk EI, Repina TV, Chermoshentsev AA. Influence of narrowband 311 nm phototherapy on the level of DNA’s damage of molecular blood cells in psoriasis patients. Russ J Skin Venereal Diseases. 2017;20(2):115. (In Russ). doi: 10.17816/dv37315
  16. Vladimirov VV, Olisova OY, Talybova AM. Influence of narrowband phototherapy on proliferative activity in psoriasis. Experimental Clin Dermatrkosmetol. 2011;(6):42. (In Russ).
  17. Breuckmann F, von Kobyletzki G, Avermaete A, et al. Mechanisms of apoptosis: UVA1-induced immediate and UVB-induced delayed apoptosis in human T cells in vitro. J Eur Acad Dermatol Venereol. 2003;17(4):418–429. doi: 10.1046/j.1468-3083.2003.00761.x
  18. Prasad R, Katiyar S. Prostaglandin E2 Promotes UV radiation-induced immune suppression through DNA hypermethylation. Neoplasia. 2013;15(7):795–804. doi: 10.1593/neo.13424
  19. Van TN, Van TH, Minh PP, et al. Efficacy of narrow ― band UVB phototherapy versus PUVA chemophototherapy for psoriasis in vietnamese patients. Open Access Maced J Med Sci. 2019;7(2): 227–230. doi: 10.3889/oamjms.2019.057
  20. Tahir R, Mujtaba G. Comparative efficacy of psoralen ― UVA photochemotherapy versus narrow band UVB phototherapy in the treatment of psoriasis. J Coll Physicians Surg Pak. 2004;14(10):593–595. doi: 10.2004/JCPSP.593595
  21. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142(7):836–842. doi: 10.1001/archderm.142.7.836
  22. Banerjee S, Das S, Roy AK, Ghoshal L. Comparative effectiveness and safety of methotrexate versus PUVA in severe chronic stable plaque psoriasis. Indian J Dermatol. 2021;66(4):371–377. doi: 10.4103/ijd.IJD_492_20
  23. Inzinger M, Heschl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol. 2011;165(3):640–645. doi: 10.1111/j.1365-2133.2011.10396.x
  24. Noe MH, Wan MT, Shin DB, et al. Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: a randomized controlled study. J Am Acad Dermatol. 2019;81(4):923–930. doi: 10.1016/j.jaad.2019.05.080
  25. Hsu K, Champaiboon C, Guenther BD, et al. Anti-Infective Protective Properties of S100 Calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009;8(4):290–305. doi: 10.2174/187152309789838975
  26. Perera C, McNeil HP, Geczy CL. S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol. 2010;88(1):41–49. doi: 10.1038/icb.2009.88
  27. Eckert RL, Broome AM, Ruse M, et al. S100 proteins in the epidermis. J Invest Dermatol. 2004;123(1):23–33. doi: 10.1111/j.0022-202X.2004.22719.x
  28. Chimenti MS, Triggianese P, Botti E, et al. S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis. J Int Med Res. 2016;44(1 Suppl):33–37. doi: 10.1177/0300060515598900
  29. Racz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol. 2011;131(7): 1547–1558. doi: 10.1038/jid.2011.53
  30. Benoit S, Toksoy A, Ahlmann M, et al. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol. 2006;155(1):62–66. doi: 10.1111/j.1365-2133.2006.07198.x
  31. Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:696415. doi: 10.1155/2014/696415
  32. Aochi S, Tsuji K, Sakaguchi M, et al. Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. J Am Acad Dermatol. 2011;64(5):879–887. doi: 10.1016/j.jaad.2010.02.049
  33. Duvetorp A, Söderman J, Assarsson M, et al. Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8/A9 protein levels in serum. PLoS One. 2019;14(3):e0213344. doi: 10.1371/journal.pone.0213344
  34. Aizawa N, Ishiuji Y, Tominaga M, et al. Relationship between the degrees of itch and serum lipocalin-2 levels in patients with psoriasis. J Immunol Res. 2019;2019:8171373. doi: 10.1155/2019/8171373
  35. Lin HH, Liao CJ, Lee YC, et al. Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci. 2011;7(1):74–86. doi: 10.7150/ijbs.7.74
  36. Romaní J, Caixàs A, Ceperuelo-Mallafré V, et al. Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res. 2013;305(2):105–112. doi: 10.1007/s00403-012-1306-5
  37. Wolk K, Frambach Y, Jacobi A, et al. Increased levels of lipocalin 2 in palmoplantar pustular psoriasis. J Dermatol Sci. 2018;90(1):68–74. doi: 10.1016/j.jdermsci.2017.12.018
  38. Shao S, Cao T, Jin L, et al. Increased lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion. J Invest Dermatol. 2016;136(7):1418–1428. doi: 10.1016/j.jid.2016.03.002
  39. Hau CS, Kanda N, Tada Y, et al. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J Dermatol. 2016;43(7):785–94. doi: 10.1111/1346-8138.13227
  40. Colak S, Omma A, Sandikci SC, et al. Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis. Bratisl Lek Listy. 2019;120(1):65–69. doi: 10.4149/BLL_2019_010
  41. Ferreira MC, Whibley N, Mamo AJ, et al. Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis. Infect Immun. 2014;82(3):1030–1035. doi: 10.1128/IAI.01389-13
  42. Wang D, Fang L, Pan G. Association of serum lipocalin-2 concentrations with psoriasis and psoriatic arthritis: an updated meta-analysis. Dis Markers. 2019;2019:7361826. doi: 10.1155/2019/7361826
  43. Koch A, Gressner OA, Sanson E, et al. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care. 2009;13(3):R95. doi: 10.1186/cc7925
  44. Maillard V, Froment P, Rame C, et al. Expression and effect of resistin on bovine and rat granulosa cell steroidogenesis and proliferation. Reproduction. 2011;141(4):467–479. doi: 10.1530/REP-10-0419
  45. Axelsson J, Heimburger O, Lindholm B, et al. Adipose tissue and its relation to inflammation: the role of adipokines. J Renal Nutr. 2005;15(1):131–136. doi: 10.1053/j.jrn.2004.09.034
  46. Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981–1000. doi: 10.1016/j.autrev.2014.07.001
  47. Huang H, Shen E, Tang S, et al. Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids Health Dis. 2015;14:44. doi: 10.1186/s12944-015-0039-9
  48. Zhu KJ, Shi G, Zhang C, et al. Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol. 2013;40:438–442. doi: 10.1111/1346-8138.12121
  49. Zhu KJ, Zhang C, Li M, et al. Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol. 2013;38(5): 478–483. doi: 10.1111/ced.12171
  50. Takahashi H, Tsuji H, Honma M, et al. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res. 2013;305(2):113–136. doi: 10.1007/s00403-012-1310-9
  51. Kawashima K, Torii K, Furuhashi T, et al. Phototherapy reduces serum resistin levels in psoriasis patients. Photodermatol Photoimmunol Photomed. 2011;27(3):152–155. doi: 10.1111/j.1600-0781.2011.00575.x
  52. Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):273–281. doi: 10.1111/bjd.16437
  53. Banerjee S, Das S, Roy AK, Ghoshal L. Comparative effectiveness and safety of methotrexate versus puva in severe chronic stable plaque psoriasis. Indian J Dermatol. 2021;66(4):371–377. doi: 10.4103/ijd.IJD_492_20
  54. Maleki M, Yazdanpanah MJ, Hamidi H, Jokar L. Evaluation of PUVA-induced skin side effects in patients referred to the imam reza hospital of mashhad in 2005–2007. Indian J Dermatol. 2014;59(2):209. doi: 10.4103/0019-5154.127708
  55. Chen X, Yang M, Cheng Y, et al. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev. 2013;10:CD009481. doi: 10.1002/14651858.CD009481.pub2
  56. Schiener R, Brockow T, Franke A, et al. Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol. 2007;143(5):586–596. doi: 10.1001/archderm.143.5.586
  57. Dawe RS, Cameron H, Yule S, et al. A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemo- therapy for psoriasis. Br J Dermatol. 2003;148(6): 1194–1204. doi: 10.1046/j.1365-2133.2003.05482.x
  58. Zhilova MB. Efficacy and safety of multiple courses of phototherapy for psoriasis. Molecular-genetics aspects of cancerogenic risk [dissertation abstract]. Moscow; 2015. 43 p. (In Russ).
  59. Schulman JM, Fisher DE. Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol. 2009;21(2):144–149. doi: 10.1097/CCO.0b013e3283252fc5
  60. Salvador JM, Perez-Ferriols A, Alegre de Miquel V, et al. Incidence of non-melanoma skin cancer in patients treated with psoralen and ultraviolet A therapy. Med Clin (Barc). 2019;152(12):488–492. doi: 10.1016/j.medcli.2018.09.018
  61. Maiorono A, Simone C, Perino F. Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy. J Dermatological Treatment. 2016;27(5):443–447. doi: 10.3109/09546634.2015.1133882
  62. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):22–31. doi: 10.1111/j.1468-3083.2012.04520.x
  63. Hearn RM, Kerr AC, Rahim KF, et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008;159(4):931–935. doi: 10.1111/j.1365-2133.2008.08776.x
  64. Smirnov KV. Long-term results of PUVA-therapy in psoriasis [dissertation abstract]. Moscow; 2008. 29 р. (In Russ).

Copyright (c) 2022 Eco-Vector



Свидетельство о регистрации СМИ № 015912 от 28.03.1997 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор). 
Свидетельство о регистрации СМИ ЭЛ № ФС 77 - 80653 от 15.03.2021 г. выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies